GLHAM member, Medicines Development for Global Health, is the first pharmaceutical company to receive US approval for the drug moxidectin, which treats river blindness. This is the only second new treatment for this debilitating disease in over 30 years. For all the hard work and sleepless nights, founder, Managing Director and Board Member, Mark Sullivan has been named this year’s Victorian Australian of the Year.
Read more here:
Victorian Australian of the Year Mark Sullivan recognised for his sight-saving medication
Melbourne medicine developer Mark Sullivan our Victorian of the year